Market Introduction Biosafety Cabinets are efficient devices that are used for controlling the contamination in laboratories dealing with infectious agents.Theses act as a primary barrier for restricting the escape of biological aerosols in the lab environment.
The biosafety cabinets are broadly classified in three types that include class I cabinets, class II cabinets and class III cabinets. There are specific regulations and guidelines imposed by the medical ruling authorities in each region that recommends the use of appropriate type of biosafety cabinet to carry out protocols based on the levels of risk involved.
Market Overview and Dynamics The North Americabiosafety cabinets market is projectedto reach US$ 147.31 millionby2027 from US$ 76.62 millionin 2019. The market is anticipated to grow with a CAGR of 8.5% from 2020 to 2027. Factors driving the market growth include increasing research activities, accelerating drug & vaccines production due to considerable prevalence of infectious diseases, and increasing number of product launches. However, the high cost involved in the installation and maintenance of biosafety cabinetsis likely to have a negative impact on the market growth.
Key Market Segments Based ontype, the class II type segment accounted for a largershare ofthe North Americabiosafety cabinets market in 2019. In terms of end user, the pharmaceutical and biopharmaceutical companies segment held a largershare of the biosafety cabinets market in North America.
Major Sources and Companies Listed A few major primary and secondary sources referred towhile preparing the North Americabiosafety cabinets market report are World Health Organization, Ministry of Health and Prevention, and Ministry of Health and Family Welfare.
NORTH AMERICABIOSAFETY CABINETS MARKET SEGMENTATION By Type • Class I • Class II • Class III By End User • Diagnostic and Testing Laboratories • Academic and Research Institutions • Pharmaceutical and Biopharmaceutical Companies • Other End Users By Country • US • Canada • Mexico Company Profiles • Esco Group of Companies • Thermo Fisher Scientific Inc. • Azbil Telstar • Baker • NuAire Inc.
Our reports have been used by over 10K customers, including:
The microcarriers market is projected to reach USD 2.9 billion by 2026 from USD 1.7 billion in 2021, at a CAGR of 10.7% during the forecast period. Increasing use of single-use bioreactors for bioprocessing, rising investmnet in R&D for developemnt of vaccines and therapeutic protiens, and increasing government funding for cell and gene therapy. •...
The global recombinant proteins market is projected to reach USD 1.7billion by 2026 from USD 1.0billion in 2021, at a CAGR of 9.8% during the forecast period. The market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industryacademia collaborations,...
The microcarrier market is majorly driven by factors such as rising demand for cell-based vaccines and therapeutics, the rapid growth of biologics and biosimilar industry, and increasing R&D and availability of funding for cell therapy research. Many of the current biologics in the pipeline are targeting the indications, which are small-molecule...
243 pages •
By Asia Market Information & Development Company
• Apr 2021
China’s demand for Biologics has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
Executive Summary Global Biologics Safety Testing Market was valued at USD 3463.90 Million in the year 2020. Major factors driving the growth of this market are the growth in pharmaceutical and biotechnology industry driven by government support, the positive trend of R&D investment in the life science sector, increasing...
The global biologics CDMO market (henceforth, referred to as the market studied) was valued at USD 9.93 billion in 2020, and it is expected to reach USD 18.90 billion by 2026, registering a CAGR of 11.2% during 2021-2026 (henceforth, referred to as the forecast period).? - The global pharmaceutical industry is growing at an exponential...
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
The anti-money laundering solution market was valued at US$ 1,503.99 million in 2019 and is projected to reach US$ 5,866.51 million by 2027; it is expected to grow at a CAGR of 16.2% from 2020 to 2027. Transaction monitoring is a crucial procedure and key control in anti-money laundering (AML) and countering the financing of terrorism (AML/CFT)...
310 pages •
By Roots Analysis Private Ltd.
• Nov 2020
INTRODUCTION With six approved drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), and more than 200 in the pipeline (clinical / preclinical stages), antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics....
The fill finish manufacturing market was valued at US$ 6,129.03 million in 2019 and is projected to reach US$ 12,547.23 million by 2027; it is expected to grow at a CAGR of 9.6% from 2020 to 2027. The growth of the fill finish manufacturing market is mainly attributed to factors such as rising adoption of prefilled syringes for parenteral...
Biopharmaceutical
Infectious Disease
World
APAC
Europe
Chronic Disease Prevalence
Health Expenditure
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.